Caris Life Sciences, Inc. CAI
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 96.06M | 105.14M | 33.98M | -68.09M | -186.99M |
| Total Depreciation and Amortization | 22.50M | 20.76M | 20.64M | 22.62M | 27.39M |
| Total Amortization of Deferred Charges | 3.84M | 5.99M | 13.45M | 12.77M | 14.07M |
| Total Other Non-Cash Items | 106.24M | 99.76M | 117.46M | 148.99M | 125.99M |
| Change in Net Operating Assets | -144.75M | -63.09M | -38.16M | -33.13M | 19.00M |
| Cash from Operations | 83.89M | 168.56M | 147.37M | 83.16M | -546.00K |
| Capital Expenditure | -54.98M | -44.60M | -23.91M | -16.26M | -13.46M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.12M | -100.12M | -- | -- | 0.00 |
| Cash from Investing | -155.09M | -144.72M | -23.91M | -16.26M | -13.46M |
| Total Debt Issued | 393.50M | 393.50M | 27.87M | 27.87M | 27.87M |
| Total Debt Repaid | -406.47M | -406.45M | -124.00K | -106.00K | -88.00K |
| Issuance of Common Stock | 32.85M | 9.61M | 535.58M | 536.10M | 532.51M |
| Repurchase of Common Stock | -37.22M | -43.67M | -18.70M | -18.66M | -18.24M |
| Issuance of Preferred Stock | 0.00 | 0.00 | 121.24M | 121.24M | 121.24M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.11M | -6.77M | -1.34M | -1.44M | -1.47M |
| Cash from Financing | -18.45M | -53.78M | 664.53M | 664.99M | 661.82M |
| Foreign Exchange rate Adjustments | -178.00K | -4.00K | 116.00K | 130.00K | 158.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.83M | -29.94M | 788.10M | 732.01M | 647.97M |